CorMedix Inc (CRMD)vsBeiGene, Ltd. (ONC)
CRMD
CorMedix Inc
$6.46
+0.62%
HEALTHCARE · Cap: $494.06M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 1614% more annual revenue ($5.34B vs $311.71M). CRMD leads profitability with a 52.3% profit margin vs 5.4%. CRMD trades at a lower P/E of 3.1x. CRMD earns a higher WallStSmart Score of 70/100 (B-).
CRMD
Strong Buy70
out of 100
Grade: B-
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.4%
Fair Value
$13.87
Current Price
$6.46
$7.41 discount
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 67 in profit
Keeps 52 of every $100 in revenue as profit
Strong operational efficiency at 53.9%
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
3.1% revenue growth
Smaller company, higher risk/reward
Earnings declined 28.3%
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : CRMD
The strongest argument for CRMD centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 52.3% and operating margin at 53.9%.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : CRMD
The primary concerns for CRMD are Revenue Growth, Market Cap, EPS Growth.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
CRMD profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
CRMD carries more volatility with a beta of 1.42 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
CRMD scores higher overall (70/100 vs 42/100), backed by strong 52.3% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CorMedix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?